AbCellera获1.05亿美元B轮融资，推动抗体药物发现平台

May 27, 2020 05:00 AM Eastern Daylight Time VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced today that it has closed a US$105 million Series B financing. The financing was led by OrbiMed and current investor DCVC Bio, with an investor syndicate that includes Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, University of Minnesota, and Presight Capital. With the proceeds of the financing, AbCellera will expand its capacity and invest in technologies that complement and extend its proprietary antibody discovery engine.
（以上内容由医药魔方AI生成）